Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels

Rheumatology (United Kingdom)

Volumn 55, Issue 11, 2016, Pages 2050-2055

  Jani, Meghna ^a   Isaacs, John D ^b,c   Morgan, Ann W ^d   Wilson, Anthony G ^e   Plant, Darren ^a,f   Hyrich, Kimme L ^a,g   Chinoy, Hector ^f,h   Barton, Anne ^a,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Newcastle Biomedical Research Centre   (United Kingdom)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^g Regional Hepatobiliary Surgery Unit   (United Kingdom)

^h Centre for Musculoskeletal Research   (United Kingdom)

Author keywords

Adalimumab; Anti drug antibodies; Anti TNF; Drug levels; ELISA; Human anti human antibodies; Immunogenicity; RIA; Therapeutic drug monitoring; TNF inhibitors

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ANTIBODY; ANTIRHEUMATIC AGENT;

ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM;

ADALIMUMAB; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY;

EID: 84997471475     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew299     Document Type: Article

References (15)

1. van Schie KA, Hart MH, de Groot ER et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:311-4.
2. Garcê s S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
3. Vincent FB, Morand EF, Murphy K et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
4. Sethu S, Govindappa K, Alhaidari M et al. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp 2012;60:331-44.
5. Jani M, Chinoy H, Warren RB et al. Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 2015;67:2011-9.
6. Potter C, Cordell HJ, Barton A et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFkB signalling pathways. Ann Rheum Dis 2010;69:1315-20.
7. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
9. Bartelds G, Krieckaert C. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
10. Hart MH, de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203.
11. Chen D-Y, Chen Y-M, Tsai W-C et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2015;74:e16.
12. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-62.
13. Bloem K, van Leeuwen A, Verbeek G et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015;418:29-38.
14. Jamnitski A, Krieckaert CL, Nurmohamed MT et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
15. Jamnitski A, Bartelds GM, Nurmohamed MT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70:284-8.